uniQure N.V. (QURE) Stockholders: Deadline for Securities Fraud Class Action is April 13, 2026

Investors who invested in uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, are now confronted by a securities fraud class action lawsuit filed by Kessler Topaz Meltzer & Check, LLP. This lawsuit, identified as Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was initiated in the United States District Court for the Southern District of New York.

The complaint filed by investors highlights uniQure as a biotechnology company that specializes in developing gene therapies for rare diseases, notably Huntington’s disease (HD). Based in The Netherlands with its primary executive headquarters in Amsterdam, uniQure’s flagship drug candidate is AMT-130, a groundbreaking gene therapy aimed at impeding the progression of HD. Known as an inherited genetic disorder that devastates nerve cells in the brain, HD triggers a spectrum of challenges related to movement, cognition, and mental health. The absence of a cure or FDA-approved method to decelerate the disease undertakes a severe toll on patients. However, AMT-130, distinguished as one of the few experimental drugs in trials to combat this illness, has established significant momentum in this field. As of March 2022, uniQure concluded patient enrollment across two paramount Phase I/II clinical trials for AMT-130, designated as the Pivotal Phase I/II Study of AMT-130 aimed at patients afflicted with HD.

Throughout this process, the FDA had reportedly agreed that the Pivotal Study would not involve a placebo comparator. Instead, the results of this study could be juxtaposed against an external historical data pool, referred to as Enroll-HD or ENROLL-HD. Encouraged by CEO Matthew Kapusta’s affirmations of the company’s alignment with the FDA during investor calls in June and July of 2025, markets expressed enthusiasm before the Class Period formally commenced on September 24, 2025. On this date, the announcement of topline findings from the Pivotal Study catapulted uniQure stock prices. The disclosure of a reduction in cerebrospinal neurofilament light protein (CSF NfL) post-AMT-130 treatment was presented as pivotal evidence supporting the drug’s efficacy in curbing neurodegeneration in HD patients. The ensuing investor conference echoed optimism from executives, explicitly endorsing AMT-130’s disease-altering abilities and hinting at an impending BLA submission for FDA acceleration.

Predictably, the market reacted favorably to the promised milestones, with uniQure shares surging from $13.66 on September 23, 2025, to $47.50 on September 24, 2025, translating to a staggering 250% increase. By October 29, 2025, investor interest in uniQure reached new heights as stock prices exceeded $70.00 per share, reflecting the collective conviction in AMT-130’s FDA approval potential. However, the subsequent downfall stems from allegations hurled by investors over misleading promotions on the drug’s viability, culminating in a burgeoning legal tussle for uniQure amid the fraud allegations.